Trinity Biotech (TRIB) Receivables - Other (2014 - 2025)

Trinity Biotech (TRIB) has reported Receivables - Other for 11 consecutive years, with $16000.0 the latest figure, recorded in Q4 2025.

• Quarterly Receivables - Other fell 90.48% year-over-year to $16000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $16000.0 (down 90.48% YoY) and the FY2025 annual result came in at $16000.0, down 90.48% from the prior year.
• Receivables - Other declined to $16000.0 in Q4 2025 per TRIB's latest filing, from $168000.0 in the prior quarter.
• Over the last five years, Receivables - Other for TRIB reached as high as $13.1 million in Q4 2021 and fell as low as $16000.0 in Q4 2025.
• A 4-year average of $3.4 million and a median of $137500.0 in 2023 frame the typical range for Receivables - Other.
• Annual changes were most pronounced in 2021 — Receivables - Other soared 116.55% — and 2025, when it plunged 90.48%.
• Year by year, Receivables - Other stood at $13.1 million in 2021, then tumbled by 99.19% to $107000.0 in 2023, then jumped by 57.01% to $168000.0 in 2024, then tumbled by 90.48% to $16000.0 in 2025.
• According to Business Quant data, Receivables - Other over the past three periods registered $16000.0, $168000.0, and $107000.0 for Q4 2025, Q4 2024, and Q4 2023 respectively.